268 related articles for article (PubMed ID: 24601828)
21. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters.
Maes L; Germonprez N; Quirijnen L; Van Puyvelde L; Cos P; Vanden Berghe D
Antimicrob Agents Chemother; 2004 Jun; 48(6):2056-60. PubMed ID: 15155199
[TBL] [Abstract][Full Text] [Related]
22. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters.
Agrawal AK; Agrawal A; Pal A; Guru PY; Gupta CM
J Drug Target; 2002 Feb; 10(1):41-5. PubMed ID: 11996085
[TBL] [Abstract][Full Text] [Related]
23. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
[TBL] [Abstract][Full Text] [Related]
24. Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies.
Asthana S; Gupta PK; Jaiswal AK; Dube A; Chourasia MK
Pharm Res; 2015 Aug; 32(8):2663-77. PubMed ID: 25715698
[TBL] [Abstract][Full Text] [Related]
25. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
Murray HW
Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
[No Abstract] [Full Text] [Related]
26. Improvising anti-leishmanial activity of amphotericin B and paromomycin using co-delivery in d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) tailored nano-lipid carrier system.
Parvez S; Yadagiri G; Singh A; Karole A; Singh OP; Sundar S; Mudavath SL
Chem Phys Lipids; 2020 Sep; 231():104946. PubMed ID: 32621810
[TBL] [Abstract][Full Text] [Related]
27. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys.
Berman JD; Hanson WL; Chapman WL; Alving CR; Lopez-Berestein G
Antimicrob Agents Chemother; 1986 Dec; 30(6):847-51. PubMed ID: 3813512
[TBL] [Abstract][Full Text] [Related]
28. Design and antileishmanial activity of amphotericin B-loaded stable ionic amphiphile biovector formulations.
Loiseau PM; Imbertie L; Bories C; Betbeder D; De Miguel I
Antimicrob Agents Chemother; 2002 May; 46(5):1597-601. PubMed ID: 11959611
[TBL] [Abstract][Full Text] [Related]
29. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes.
Kar N; Chakraborty S; De AK; Ghosh S; Bera T
Eur J Pharm Sci; 2017 Jun; 104():196-211. PubMed ID: 28400285
[TBL] [Abstract][Full Text] [Related]
30. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes.
Prajapati VK; Awasthi K; Gautam S; Yadav TP; Rai M; Srivastava ON; Sundar S
J Antimicrob Chemother; 2011 Apr; 66(4):874-9. PubMed ID: 21393222
[TBL] [Abstract][Full Text] [Related]
31. An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis.
Prajapati VK; Awasthi K; Yadav TP; Rai M; Srivastava ON; Sundar S
J Infect Dis; 2012 Jan; 205(2):333-6. PubMed ID: 22158723
[TBL] [Abstract][Full Text] [Related]
32. Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid-polymer hybrid nanoparticle: biodistribution and toxicity assessment of encapsulated amphotericin B.
Asthana S; Jaiswal AK; Gupta PK; Dube A; Chourasia MK
Eur J Pharm Biopharm; 2015 Jan; 89():62-73. PubMed ID: 25477079
[TBL] [Abstract][Full Text] [Related]
33. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease.
Hu K; Shi Y; Jiang W; Han J; Huang S; Jiang X
Int J Pharm; 2011 Aug; 415(1-2):273-83. PubMed ID: 21651967
[TBL] [Abstract][Full Text] [Related]
34. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828
[TBL] [Abstract][Full Text] [Related]
35. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis.
Gupta S; Dube A; Vyas SP
J Drug Target; 2007 Jul; 15(6):437-44. PubMed ID: 17613662
[TBL] [Abstract][Full Text] [Related]
36. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer.
Chen J; Li S; Shen Q; He H; Zhang Y
Drug Dev Ind Pharm; 2011 Nov; 37(11):1339-46. PubMed ID: 21524153
[TBL] [Abstract][Full Text] [Related]
37. Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis.
Afzal I; Sarwar HS; Sohail MF; Varikuti S; Jahan S; Akhtar S; Yasinzai M; Satoskar AR; Shahnaz G
Nanomedicine (Lond); 2019 Feb; 14(4):387-406. PubMed ID: 30688557
[TBL] [Abstract][Full Text] [Related]
38. Amphotericin B-loaded polymeric nanoparticles: formulation optimization by factorial design.
Carraro TC; Khalil NM; Mainardes RM
Pharm Dev Technol; 2016 Mar; 21(2):140-6. PubMed ID: 25384838
[TBL] [Abstract][Full Text] [Related]
39. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
Paila YD; Saha B; Chattopadhyay A
Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487
[TBL] [Abstract][Full Text] [Related]
40. Oleanolic acid loaded poly lactic co- glycolic acid- vitamin E TPGS nanoparticles for the treatment of Leishmania donovani infected visceral leishmaniasis.
Ghosh S; Kar N; Bera T
Int J Biol Macromol; 2016 Dec; 93(Pt A):961-970. PubMed ID: 27645930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
